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INTRODUCTION
Farkouh et al. [1] in their letter to the editor in
response to the publication entitled ‘‘Cost-
Effectiveness Evaluation of the 10-Valent
Pneumococcal Non-typeable Haemophilus
influenzae Protein D Conjugate Vaccine and
13-Valent Pneumococcal Vaccine in Japanese
Children’’ [2] raise questions concerning the
efficacy and effectiveness assumptions made for
both vaccines.
We agree with Farkouh et al. [1] that the
validity of any cost-effectiveness model relies
upon both the ability of the model to reflect the
reality of complex clinical and epidemiological
scenarios and the quality of the input data. In
the absence of head-to-head studies comparing
the clinical efficacy of the two pneumococcal
conjugate vaccines (PCV), validation of the
assumptions used in the model is essential. In
the case of our model, contrary to the opinion
of Farkouh et al. [1], the assumptions are based
on the most recent, publicly available clinical
evidence. In reflection of the variable
robustness of the available evidence, the
assumptions were validated by two
independent advisory boards (including one
undertaken specifically to support the analysis
in Japan), each consisting of prominent experts
in the field. This was particularly important for
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the 13-valent PCV (PCV-13), since the data for
that vaccine is largely derived from post-
marketing surveillance studies that are subject
to several different confounding factors, as
opposed to results of randomized, double-
blind clinical trials, which are considered to be
of the highest standard for assessing vaccine
efficacy. The latter are only available for the ten-
valent pneumococcal non-typeable
Haemophilus influenzae protein D conjugate
vaccine (PHiD-CV), and data from post-
marketing surveillances with PHiD-CV
corroborate findings of these randomized trials.
As most of the concerns raised by Farkouh
et al. [1] have already been addressed in the
scenario and sensitivity analyses presented in
our original publication [2], in this response we
will largely discuss those assumptions which
were not previously elaborated upon [2].
EFFECTIVENESS AGAINST
PNEUMONIA
While the suggestion by Farkouh et al. [1] to
assume that the individual effectiveness of
vaccines is proportional to their serotype
coverage seems straightforward, the real-world
experience with various PCVs does not support
such a close relationship. In fact, based on a
critical appraisal of clinical evidence for all
marketed as well as many investigational
pneumococcal conjugate PCVs, Hausdorff
et al. [3] convincingly argued that the serotype
coverage of PHiD-CV and PCV-13 vaccines is an
inadequate basis for making quantitative
projections regarding the overall disease
impact [3]. One major reason is that such a
simplistic approach does not adequately
account for protection against vaccine-related
serotypes, while there is substantial, growing
evidence in the literature that PCVs can provide
substantial protection against those [3].
Moreover, randomized double-blind trials
assessing efficacy against pneumonia do not
suggest that higher valence vaccines, even
beyond the ten-valent formulation [3], offer
greater protection against clinical or
radiologically confirmed pneumonia. Finally,
PHiD-CV efficacy to prevent pneumonia in
children was demonstrated in two large
randomized, double-blind clinical trials [4, 5]
and corroborated during post-marketing
surveillance (for example, in Brazil [6], Finland
[7], and Iceland [8]), whereas the evidence for
PCV-13 is based solely on data from post-
marketing surveillance studies [9–14]. As
mentioned earlier, this poses difficulties in
comparison, as due to a variety of factors
inherent in these latter studies, such as
differences in populations, schedules, uptake
rates, timing and other variables that affect
disease rates within an uncontrolled
effectiveness or impact analysis, it is very
difficult to draw meaningful quantitative or
comparative conclusions.
The complexity of interpreting post-
marketing impact studies is perhaps best
illustrated by a study from Sweden [15]
referred to also by Farkouh et al. [1], where
currently both PHiD-CV and PCV-13 are used in
different county councils. Differences in
pneumonia hospitalization incidence were
observed between the respective councils and
it was suggested that this can be attributed to
the difference in the valence of PCVs used [1].
However, as reported in that paper [15], the
seven-valent PCV (PCV-7) was introduced in all
those councils in Sweden prior to the use of
higher valent vaccines, and yet the magnitude
of reduction of pneumonia incidence observed
during the period when only PCV-7 was used
still differed markedly in those respective
councils, which are currently using either
PCV-13 or PHiD-CV. This observation strongly
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suggests that any observed differences in
pneumonia incidence between the councils
mainly reflect other epidemiological factors or
secular trends that differ in the two
populations, rather than true differences in
efficacy against pneumonia of either PCV-13
or PHiD-CV. In conclusion, the concept that
overall protection is governed predominantly
by serotype coverage is unsupported by the
clinical evidence [3] and support the efficacy
estimates used in our published model [2].
PROTECTION AGAINST CROSS-
REACTIVE SEROTYPES
With respect to protection against cross-reactive
serotypes not included in PHiD-CV
formulation, our assumptions for vaccine
effectiveness against serotypes 19A and 6A are,
in contrast to the opinion of Farkouh et al. [1],
largely based on data generated with this
vaccine in a number of studies of robust
design. Data generated with other
formulations are also strongly supportive of
our assumptions.
Data from various post-marketing studies
provide evidence for PHiD-CV protection
against serotype 19A [16]. The 82%
effectiveness of PHiD-CV against 19A invasive
pneumococcal disease (IPD) reported in the
Brazilian case–control study [17] has been
corroborated in two additional robustly
designed studies in Quebec (Canada) and
Finland, respectively. In the Quebec case–
control study [18], the effectiveness of PHiD-
CV against serotype 19A was 71%, which was
statistically significant. This study, which is
unique in also assessing the effectiveness of
PCV-13 on 19A disease in the same study
setting, demonstrated vaccine effectiveness of
74% for PCV-13 (overlapping confidence
intervals with PHiD-CV) [18]. In the Finnish
cohort study, a significant 62% reduction in a
number of 19A IPD cases was observed
following the introduction of PHiD-CV into
their national immunization program (NIP)
[19]. Additional data supporting the
effectiveness of PHiD-CV in their NIP,
including the Netherlands [20, 21] and Chile
[22], as well as the functional opsonophagocytic
antibody (OPA) responses against 19A
(functional OPAs are generally agreed to be
the mechanism of protection) have been fully
described in recent reviews by Hausdorff et al.
[23], Clarke et al. [24] and Mrkvan et al. [25].
Evidence from post-marketing surveillance
studies indicate that PHiD-CV also prevents
disease caused by serotype 6A. The cohort study
in Finland also described a significant 100%
(95% CI: 41%; 100%) reduction in 6A IPD cases
following PHiD-CV introduction into the NIP
[26]. Another example is Chile, where at least
ten 6A IPD cases in children below 2 years of
age were recorded annually in each of the
4 years before PHiD-CV was introduced in 2011
(average of 18 cases per year), but only five
cases were reported in 2012 [22]. It should be
noted that evidence for the effectiveness of
PHiD-CV against serotype 6A is somewhat
more limited than for serotype 19A. This is
because countries where PCV-7 was
implemented to NIP before PHiD-CV had little
or negligible residual serotype 6A IPD due to
substantial cross protection provided by the
6B conjugate in PCV-7 [3]. Studies using
different schedules and conducted in different
populations have also consistently
demonstrated that PHiD-CV, similarly to
PCV-7, elicits robust functional OPA responses
against serotype 6A. Notably, the antibody
levels elicited by PHiD-CV against cross-
reactive serotypes 6A and 19A were especially
higher in Japanese infants in comparison with
other populations [27].
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In summary, data generated during post-
marketing surveillance, as well as the
immunogenicity results from randomized
double-blind studies, strongly support the
validity of our assumptions made for
protection conferred by PHiD-CV against
infections caused by the cross-reactive
serotypes 19A and 6A.
EFFECTIVENESS AGAINST ACUTE
OTITIS MEDIA
Farkouh et al. [1] further question the
assumptions specific to acute otitis media
(AOM). A vaccine efficacy of 19% for PHiD-CV
against clinically confirmed AOM was
demonstrated in the large randomized, double-
blind COMPAS study [4]. Corresponding data
from a randomized clinical trial are not
available for PCV-13. As with PCV-13,
significant reductions in the burden of AOM
have been observed with PHiD-CV in countries
where the vaccine has been included in their
NIP. For instance, a time series database analysis
in Goiania (Brazil) indicated that medical visits
for all-cause AOM in 2- to 23-month-olds were
45% lower after the introduction of PHiD-CV
[28]. In Iceland, the annual incidence of
hospital visits/admissions attributable to AOM
was 24% lower in children younger than
2 years, who were born within 1 year of the
introduction of PHiD-CV [8]. However, as
already discussed above in the context of post-
marketing surveillance studies addressing
pneumonia, it is rather difficult to draw
meaningful quantitative conclusions regarding
vaccines used in different populations from
post-marketing surveillance.
Our model therefore relies on extrapolations,
made by the expert panels, of assumptions of
vaccine efficacy against the major pathogens
causing bacterial AOM, Streptococcus pneumoniae
and non-typeable Haemophilus influenzae
(NTHi), derived from available randomized
trials. Although the efficacy data for PCV-13
against pneumococcal AOM are lacking, it
should be noted that whenever the vaccine
efficacy against vaccine-type (VT)
pneumococcal AOM was assessed for PCVs
(PCV-7, the 7-valent conjugate vaccine with
outer membrane protein carrier (7vOMP), the
11-valent pneumococcal conjugate vaccine
with protein D of Haemophilus influenzae as a
carrier (11PnPD), and PHiD-CV), it [4, 29–31]
was similar, so it is reasonable to assume that it
would not be a lot different for PCV-13.
With respect to efficacy against NTHi-AOM,
although the COMPAS trial was not powered to
provide conclusive evidence, the positive point
estimate of PHiD-CV efficacy against NTHi
(22%; 95% CI: -43%; 57%) is [4] consistent
with the significant efficacy observed with the
predecessor protein D conjugate formulation in
the POET study (35%; 95% CI: 2%; 57%) [31].
The positive point estimates for efficacy against
NTHi OM observed in COMPAS and POET are in
contrast with the negative point estimates
observed in studies of non-protein D
containing PCV formulations, including CRM
conjugates [4, 29–31]. In addition, there is
concordant body of pre-clinical and
immunological evidence (reviewed in detail in
[32, 33]), lending credence to the notion that
protein D containing vaccines elicit an
immunological response and offer protection
against NTHi AOM [34–37].
Despite that population-based studies
evaluating the impact of vaccines on AOM are
generally based on clinical rather than
pathogen-specific diagnoses, and therefore
cannot generally provide information on the
impact on AOM due to NTHi, further, albeit
limited, evidence of PHiD-CV impact on NTHi
disease is emerging from some post-marketing
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studies. For instance, one cross-sectional survey
study has provided information on the
prevalence of NTHi AOM in a PHiD-CV-
vaccinated population of Australian indigenous
children compared with a historical cohort of
children who had received PCV-7. Also, the
prevalence of the more severe suppurative
disease presentations were significantly lower
in the PHiD-CV cohort. Moreover, the
prevalence of NTHi was significantly lower in
the PHiD-CV cohort of children diagnosed
with suppurative disease and culturing of
otopathogens [38]. Although these findings
need to be interpreted with the same caution
as for other observational studies, they provide
an encouraging sign that protein D-based
vaccines may offer some level of protection
against disease due to NTHi.
Notwithstanding the multiple lines of
evidence above, the possibility that PHiD-CV
has no efficacy against NTHi AOM has been
explored and presented as an additional
scenario in the original paper [2].
EFFECTIVENESS AGAINST IPD
CAUSED BY SEROTYPE 3
Farkouh et al. [1] state that PCV-13 cannot be
considered ineffective against serotype 3
because the available evidence is not
conclusive at this point. We argue the
contrary, because today, several years after
introduction of PCV-13 into many national
immunization programs, there is still no
conclusive evidence that PCV-13 prevents
serotype 3 disease or provides herd protection
[39–50]. Some post-marketing surveillance
studies report no detectable change at all in
serotype 3 disease [41, 42]. Although some
studies, including the latest Joint Committee
on Vaccines and Immunization (JCVI) minutes
from the UK [51], as cited by Farkouh et al. [1],
have reported non-significant trends for
reduction, it is unclear whether these
observations should be attributed to the use of
the vaccine, or rather represent a secular
trend/natural cyclical pattern in the disease, as
have been described for a number of serotypes
[52], including serotype 3 as suggested in other
settings [40, 53]. Indeed, the most recent
published data from the UK report a
non-significant vaccine effectiveness of 26%
(95% CI: -69%; 68%) [44], a very wide
confidence interval crossing zero and a point
estimate that is remarkably lower) than the high
(and significant) effectiveness estimates
obtained for the other PCV-13 vaccine
serotypes [44]. Nonetheless, we note that the
assumption of effectiveness of PCV-13 up to
89.0% [54] against serotype 3 IPD was tested in
the sensitivity analysis of our model, revealing
no substantial impact on the model outcome.
HERD EFFECT
Farkouh et al. [1] question whether indirect
effects for VT disease have been demonstrated
and reported for both formulations, i.e., both
PCV-13 and PHiD-CV. Decreases in VT disease
in non-vaccinated cohorts have been observed
in post-marketing studies for both PCV-13 and
PHiD-CV (including Brazil, Chile, Finland and
Iceland [55]). In addition, the herd effect of
PHiD-CV has been more rigorously analyzed in
the context of a cluster randomized double-
blind study in Finland [56].
Although not mentioned by Farkouh et al.
[1], the public health value of the herd effects
remains an area of debate. Based on the
experience with PCV-7 use, the herd effect
observed for VT disease is likely to be largely
or fully offset by disease caused by circulating
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non-vaccine serotypes, a phenomenon called
serotype replacement [57, 58]. The extent of
such replacement elicited by each of the new
vaccines is a remaining area of uncertainty, and
therefore whether there will be differential net
herd effect is currently difficult to assess
conclusively [3]. In consequence, we did not
incorporate herd or indirect protection in our
analysis. Further discussion on the reasons why
herd effects were not considered for this
analysis is detailed in our original paper [2].
SUMMARY
Our analysis has considered the most up-to-date
clinical evidence, placing emphasis on data
from randomized double-blind controlled
trials, rather than having relied on theoretical
assumptions. In addition, we have consulted an
external group of experts to validate each
parameter that was used as base-case input
into the model. We hope that the evidence
provided here, in addition to what is reflected in
our original paper, testifies that we have
considered the strengths and weaknesses of all
available data to construct a sensible and
conservative base-case analysis as well as have
meticulously addressed any areas of uncertainty
using appropriate sensitivity and scenario
analyses.
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